Hypercholesteremia
18
1
1
16
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
28%
5 trials in Phase 3/4
19%
3 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (18)
Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis
The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects
The Effect of Remote Ischemic Conditioning in Patients With Hypercholesterolemia
Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
Phytosterol Supplementation and Cardiovascular Risk
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health
Pattern of Statins Use in Catalonia
Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque
Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Effects of Limicol on LDL-cholesterol
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients